Kanaph focuses on the research and development of innovative therapeutic molecules to address unmet medical needs in cancer and ophthalmology. With expertise in both large molecule and small molecule drug discovery and development, Kanaph Therapeutics utilizes novel drug discovery technology to develop first-in-class bispecific antibodies, best-in-class small molecules differentiated from existing therapies, and ADCs (antibody-drug conjugates) through a strategically differentiated approach.

Through drug discovery technology based on human genomics, we identify targets based on human genomics analysis and develop differentiated drugs by applying the optimal modalities to meet unmet medical needs

Kanaph's bispecific antibodies for immuno-oncology and ophthalmology are designed and engineered with the vision of overcoming the limitations of agents that are currently marketed or being tested in the clinic. By taking a bispecific approach, Kanaph's programs can address the multifactorial causes of diseases.

Our small molecule drug discovery efforts include the development of novel small molecules to treat hard-to-cure cancers by targeting specific mutational signaling pathways. We are also adopting novel therapeutic approaches with small molecules to eliminate immuno-suppressive environment created by tumors.